EGFRvIII - A stable target for anti-EGFRvIII therapy

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5343-5348

  Banaszczyk, Mateusz ^a   Stoczynska Fidelus, Ewelina ^a   Winiecka Klimek, Marta ^a   Bienkowsk, Michal ^a   Och, Waldemar ^b   Rieske, Piotr ^a   Piaskowski, Sylwester ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Provincial Specialist Hospital in Olsztyn   (Poland)

Author keywords

EGFR amplification; EGFRvIII; Glioblastoma; Polysomy 7p

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR V3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHROMOSOME 7; CHROMOSOME NUMBER; CONTROLLED STUDY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84891475912     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Heimberger AB, Suki D, Yang D et al: The natural history of EGFR and EGFRvIII in glioblastoma patients. Journal of Translational Medicine 3: 38, 2005.
2. Viana-Pereira M, Lopes JEM, Little S et al: Analysis of EGFR Overexpression, EGFR Gene Amplification and the EGFRvIII Mutation in Portuguese High-grade Gliomas. Anticancer Research 28: 913-920, 2008.
3. Gan HK, Kaye AH and Luwor RB: The EGFRvIII variant in glioblastoma multiforme. Journal of Clinical Neuroscience 16: 748-754, 2009.
4. Andl CD, Mizushima T, Nakagawa H et al: Epidermal Growth Factor Receptor Mediates Increased Cell Proliferation, Migration, and Aggregation in Esophageal Keratinocytes in Vitro and in Vivo. The Journal of Biological Chemistry vol. 278, no. 3: 1824, 2003.
5. Lodish H, Berk A, Matsudaira P et al: Molecular Cell Biology. Edition 6. New York 2007: 588, 593, 599-600.
6. Gururaj AE, Bögler O and Latha K: Nuclear Signaling of EGFR and EGFRvIII in Glioblastoma. Molecular Targets of CNS Tumors, Dr. Miklos Garami (Ed.), ISBN: 978-953-307-736-9, InTech, Available from: http://www.intechopen. com/books/molecular-targets-of-cns-tumors/nuclear-signaling-of-egfr-and- egfrviii-in-glioblastoma
7. Wikstrand CJ, Reist CJ, Archer GE et al: The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. Journal of NeuroVirology 4: 148-158, 1998.
8. Bienkowski M, Piaskowski S, Stoczynska-Fidelus E et al: Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients. PLoS ONE 8(6): e65444. doi:10.1371/journal.pone. 0065444
9. Shinojima N, Tada K, Shiraishi S et al: Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme. Cancer Res 63(20): 6962-6970, 2003.
10. Sesboüé R, Le Pessot F, Di Fiore F, Frebourg T et al: EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain? Br J Cancer 106(2): 426-427, 2012.
11. Ålgars A, Lintunen M, Carpén O et al: Reply: EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain? Br J Cancer 106(2): 428, 2012.
12. Marquez A, Wu R, Zhao J et al: Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol 13: 1-8, 2004.
13. Lee JC, Vivanco I, Beroukhim R et al: Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain PLoS Med 3(12): e485. doi:10.1371/journal.
14. Yung WKA, Vredenburgh JJ, Cloughesy TF, Nghiemphu P et al: Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 12(10): 1061-1070, 2010. doi: 10.1093/neuonc/noq072
15. Scott AM, Lee FT, Tebbutt N et al: A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. PNAS 104(10): 4071-4076, 2007. doi:10.1073/pnas. 0611693104
16. Hasselbalch B, Lassen U, Poulsen HS et al: Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling. Cancer Invest 28(8): 775-787, 2010. doi: 10.3109/07357907.2010.483506.
17. Idbaih A, Aimard J, Boisselier B et al: Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma. Neuropathology and Applied Neurobiology 35: 208-213, 2009.
18. Frederick L, Wang X-Y, Eley G et al: Diversity and Frequency of Epidermal Growth Factor Receptor Mutations in Human Glioblastomas. Cancer Research 60: 1383-1387, 2000.
19. Louis DN, Ohgaki H, Wiestler OD et al: The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol 114(2): 97-109, 2007.
20. Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36, 2002.
21. Layfield LJ, Willmore C, Tripp S et al: Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl Immunohistochem Mol Morphol 14: 91-96, 2006.
22. Lee J, Jang KT, Ki CS et al: Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 109(8): 1561-1569, 2007.
23. Sauter G, Haley J, Chew K et al: Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer 57: 508-514, 1994.
24. Liu L, Bäcklund ML, Nilsson BR et al: Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med (Berl) 83(11): 917-926, 2005.
25. Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170(5): 1445-1453, 2007.
26. Hassler M, Seidl S, Fazeny-Doerner B et al: Diversity of cytogenetic and pathohistologic profiles in glioblastoma. Cancer Genet Cytogenet 166(1): 46-55, 2006.
27. Sugawa N, Ekstrand AJ, Jamest CD et al: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Nati Acad. Sci. USA 87: 8602-8606, 1990.
28. Witusik-Perkowska M, Rieske P, Hułas-Bigoszewska K et al: Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies. J Neurooncol 102(3): 395-407, 2011.
29. Layfield LJ, Willmore C, Tripp S et al: Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl Immunohistochem Mol Morphol 14: 91-96, 2006.
30. Lopez-Gines C, Gil-Benso R, Monleon D et al: Primary Glioblastoma with Different Patterns of EGFR Amplification and the Relationship with Gene Expression Profile, Molecular Targets of CNS Tumors 2011, Dr. Miklos Garami (Ed.), ISBN: 978-953-307-736-9, InTech, Available at: http://www.intechopen.com/ books/molecular-targets-of-cns-tumors/primary-glioblastoma-with-different- patterns-of-egfr-amplification-and-therelationship-with-gene-ex
31. Kuan CT, Wikstrand CJ, Bigner DD: EGF mutant receptor vIII as a molecular target in cancer therapy. Endocrine-Related Cancer 8: 83-96, 2001.